In vivo 11β-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia

George Richard Thompson, Diana Chang, Rebecca R. Wittenberg, Ian Howard Mchardy, Alison Semrad

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

Original languageEnglish (US)
Article numbere00760
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Hypokalemia
Hypertension
Azoles
Recurrence
Therapeutics
posaconazole
Apparent mineralocorticoid excess

Keywords

  • Antifungal
  • Posaconazole
  • Side effects

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In vivo 11β-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia. / Thompson, George Richard; Chang, Diana; Wittenberg, Rebecca R.; Mchardy, Ian Howard; Semrad, Alison.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 8, e00760, 01.08.2017.

Research output: Contribution to journalArticle

@article{67a9e0a926cd49ada183e6ca8d13ff21,
title = "In vivo 11β-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia",
abstract = "We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.",
keywords = "Antifungal, Posaconazole, Side effects",
author = "Thompson, {George Richard} and Diana Chang and Wittenberg, {Rebecca R.} and Mchardy, {Ian Howard} and Alison Semrad",
year = "2017",
month = "8",
day = "1",
doi = "10.1128/AAC.00760-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - In vivo 11β-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia

AU - Thompson, George Richard

AU - Chang, Diana

AU - Wittenberg, Rebecca R.

AU - Mchardy, Ian Howard

AU - Semrad, Alison

PY - 2017/8/1

Y1 - 2017/8/1

N2 - We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

AB - We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

KW - Antifungal

KW - Posaconazole

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=85026427233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026427233&partnerID=8YFLogxK

U2 - 10.1128/AAC.00760-17

DO - 10.1128/AAC.00760-17

M3 - Article

C2 - 28533238

AN - SCOPUS:85026427233

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00760

ER -